GCP
KRYS icon

GSA Capital Partners’s Krystal Biotech KRYS Stock Holding History

GSA Capital Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
+1,643
New +$491K 0.04% 865
2025
Q1 		– Sell
-3,464
Closed -$543K – 1882
2024
Q4 		$543K Buy
+3,464
New +$614K 0.04% 826

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GSA Capital Partners's KRYS Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Krystal Biotech (KRYS) in Q2 2026: 1,643 shares worth $611K. The stake represents 0.04% of the portfolio and ranks #865 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in KRYS as recently as Q4 2024.

GSA Capital Partners first reported a position in KRYS in Q4 2024 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • GSA Capital Partners held 1,643 shares of Krystal Biotech worth $611K as of Q2 2026.
  • Krystal Biotech was a new GSA Capital Partners position in Q2 2026.
  • Krystal Biotech made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #865 holding.
  • GSA Capital Partners first reported a position in Krystal Biotech in Q4 2024 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.